Regencell Bioscience Holdings Ltd (RGC) - Net Assets
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has net assets worth $4.86 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.76 Million) and total liabilities ($895.31K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Regencell Bioscience Holdings Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.86 Million |
| % of Total Assets | 84.44% |
| Annual Growth Rate | -22.36% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 46.33 |
Regencell Bioscience Holdings Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Regencell Bioscience Holdings Ltd for the complete picture of this company's asset base.
Annual Net Assets for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual net assets of Regencell Bioscience Holdings Ltd from 2003 to 2025. For live valuation and market cap data, see RGC market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $4.86 Million | -40.86% |
| 2024-06-30 | $8.22 Million | -31.45% |
| 2023-06-30 | $11.99 Million | -29.81% |
| 2022-06-30 | $17.08 Million | +527.27% |
| 2021-06-30 | $-4.00 Million | -50.80% |
| 2020-06-30 | $-2.65 Million | -44.19% |
| 2019-06-30 | $-1.84 Million | +99.79% |
| 2018-06-30 | $-855.80 Million | -2.01% |
| 2017-06-30 | $-838.90 Million | +4.41% |
| 2016-06-30 | $-877.60 Million | +1.92% |
| 2015-06-30 | $-894.80 Million | -25.43% |
| 2014-06-30 | $-713.40 Million | -2.38% |
| 2013-06-30 | $-696.80 Million | -22.05% |
| 2012-06-30 | $-570.90 Million | -16.44% |
| 2011-06-30 | $-490.30 Million | -98.58% |
| 2010-06-30 | $-246.90 Million | -2.02% |
| 2009-06-30 | $-242.00 Million | -103.36% |
| 2008-06-30 | $-119.00 Million | -466.67% |
| 2007-06-30 | $-21.00 Million | -167.74% |
| 2006-06-30 | $31.00 Million | -56.34% |
| 2005-06-30 | $71.00 Million | -91.10% |
| 2004-06-30 | $798.00 Million | -37.36% |
| 2003-06-30 | $1.27 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regencell Bioscience Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 134.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.95K | 0.10% |
| Other Comprehensive Income | $-64.79K | -1.33% |
| Other Components | $30.12 Million | 619.74% |
| Total Equity | $4.86 Million | 100.00% |
Regencell Bioscience Holdings Ltd Competitors by Market Cap
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SANDS CHINA ADR/1 O.N.
F:599
|
$14.41 Billion |
|
Unibail-Rodamco-Westfield
PA:URW
|
$14.42 Billion |
|
Pinnacle Financial Partners, Inc.
NASDAQ:PNFP
|
$14.43 Billion |
|
Cemex SAB de CV ADR
F:CEXA
|
$14.44 Billion |
|
Regency Centers Corporation
NASDAQ:REG
|
$14.40 Billion |
|
ZTO EXPRESS (CAYMAN)
F:ZTOB
|
$14.39 Billion |
|
Omv Petrom S.A
RO:SNP
|
$14.38 Billion |
|
Krung Thai Bank Public Company Limited
BK:KTB
|
$14.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regencell Bioscience Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,218,699 to 4,860,274, a change of -3,358,425 (-40.9%).
- Net loss of 3,584,213 reduced equity.
- Other comprehensive income decreased equity by 19,020.
- Other factors increased equity by 244,808.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.58 Million | -73.75% |
| Other Comprehensive Income | $-19.02K | -0.39% |
| Other Changes | $244.81K | +5.04% |
| Total Change | $- | -40.86% |
Book Value vs Market Value Analysis
This analysis compares Regencell Bioscience Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2962.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 129.04x to 2962.70x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-06-30 | $0.23 | $29.12 | x |
| 2004-06-30 | $0.15 | $29.12 | x |
| 2005-06-30 | $0.01 | $29.12 | x |
| 2006-06-30 | $0.19 | $29.12 | x |
| 2007-06-30 | $-0.44 | $29.12 | x |
| 2008-06-30 | $-0.54 | $29.12 | x |
| 2009-06-30 | $-5.47 | $29.12 | x |
| 2010-06-30 | $-0.04 | $29.12 | x |
| 2011-06-30 | $-0.08 | $29.12 | x |
| 2012-06-30 | $-3.69 | $29.12 | x |
| 2013-06-30 | $-0.12 | $29.12 | x |
| 2014-06-30 | $-0.12 | $29.12 | x |
| 2015-06-30 | $-0.15 | $29.12 | x |
| 2016-06-30 | $-0.15 | $29.12 | x |
| 2017-06-30 | $-0.14 | $29.12 | x |
| 2018-06-30 | $-0.14 | $29.12 | x |
| 2019-06-30 | $0.00 | $29.12 | x |
| 2020-06-30 | $-0.01 | $29.12 | x |
| 2021-06-30 | $-0.01 | $29.12 | x |
| 2022-06-30 | $0.03 | $29.12 | x |
| 2023-06-30 | $0.02 | $29.12 | x |
| 2024-06-30 | $0.02 | $29.12 | x |
| 2025-06-30 | $0.01 | $29.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regencell Bioscience Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-73.75%) is below the historical average (10.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 9.21% | 5.47% | 0.93x | 1.82x | $-10.00 Million |
| 2004 | 23.30% | 7.43% | 1.01x | 3.11x | $105.60 Million |
| 2005 | 118.84% | 3.32% | 0.97x | 36.84x | $75.10 Million |
| 2006 | 313.79% | 3.62% | 0.99x | 87.31x | $88.10 Million |
| 2007 | 0.00% | 3.31% | 1.05x | 0.00x | $88.20 Million |
| 2008 | 0.00% | 13.64% | 1.01x | 0.00x | $374.90 Million |
| 2009 | 0.00% | 2.60% | 1.07x | 0.00x | $96.10 Million |
| 2010 | 0.00% | 3.30% | 1.10x | 0.00x | $120.11 Million |
| 2011 | 0.00% | 2.76% | 1.13x | 0.00x | $126.63 Million |
| 2012 | 0.00% | 1.50% | 1.15x | 0.00x | $97.39 Million |
| 2013 | 0.00% | 5.13% | 1.28x | 0.00x | $214.48 Million |
| 2014 | 0.00% | 5.19% | 1.12x | 0.00x | $229.04 Million |
| 2015 | 0.00% | 3.53% | 1.18x | 0.00x | $195.08 Million |
| 2016 | 0.00% | 4.91% | 1.19x | 0.00x | $241.18 Million |
| 2017 | 0.00% | 5.33% | 1.21x | 0.00x | $254.31 Million |
| 2018 | 0.00% | 3.55% | 1.11x | 0.00x | $197.89 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-207.14K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-547.28K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-946.98K |
| 2022 | -43.50% | 0.00% | 0.00x | 1.06x | $-9.13 Million |
| 2023 | -48.80% | 0.00% | 0.00x | 1.05x | $-7.07 Million |
| 2024 | -52.34% | 0.00% | 0.00x | 1.03x | $-5.12 Million |
| 2025 | -73.75% | 0.00% | 0.00x | 1.18x | $-4.07 Million |
Industry Comparison
This section compares Regencell Bioscience Holdings Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regencell Bioscience Holdings Ltd (RGC) | $4.86 Million | 9.21% | 0.18x | $14.40 Billion |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more